Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
AssigneeBoehringer Ingelheim International GmbH
InventorsWulf Otto BOECHER, Janine LAMAR, Steven John PADULA
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of inflammatory bowel disease (IBD) with anti-IL36R antibodies.
Claims45
A method of treating inflammatory bowel disease in a mammal, said method comprising administering to the mammal a therapeutically effective amount of an anti-IL-36R antibody.
A method of treating mild to severe inflammatory bowel disease in a mammal, said method comprising administering to the mammal a therapeutically effective amount of an anti-IL-36R antibody.
A method of treating ulcerative colitis in a mammal, said method comprising administering to the mammal a therapeutically effective amount of an anti-IL-36R antibody.
A method of treating Crohn's disease in a mammal, said method comprising administering to the mammal a therapeutically effective amount of an anti-IL-36R antibody.
A method of treating fistulizing Crohn's disease in a mammal, said method comprising administering to the mammal a therapeutically effective amount of an anti-IL-36R antibody.
A method of treating moderate to severe active inflammatory bowel disease in patients who have failed a previous therapy, comprising administering to said each patient a therapeutically effective amount of an anti-IL-36R antibody.
A method of treating moderate to severe active inflammatory bowel disease in adult patients, wherein each of said patients has a total MCS (Mayo Clinical Score) of 6 to 12 and has failed a previous therapy, comprising administering to said each patient a therapeutically effective amount of an anti-IL-36R antibody.
A method for reducing or inhibiting symptoms of moderate to severe active inflammatory bowel disease in adult patients, wherein each of said patients has a total MCS (Mayo Clinical Score) of 6 to 12 and has failed a previous therapy, comprising administering to said each patient a therapeutically effective amount of an anti-IL-36R antibody.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating inflammatory bowel disease in a mammal, said method comprising administering to the mammal a therapeutically effective amount of an anti-IL-36R antibody, wherein the anti-IL-36R antibody is administered in one or more induction dose and/or optionally one or more maintenance dose.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.